U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT07558525) titled 'Evaluation of Chiglitazar Sodium With Lifestyle Intervention for Reversing Prediabetes' on April 22.
Brief Summary: This multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy and safety of Chiglitazar Sodium combined with lifestyle intervention for reversing prediabetes to normal glucose metabolism. Eligible participants with prediabetes will be randomized 1:1 to receive either Chiglitazar Sodium 48 mg once daily or matching placebo, both combined with standardized lifestyle intervention, for 52 weeks, followed by a 12-week observation period and optional long-term extension. The primary endpoin...